LY 2886721

Drug Profile

LY 2886721

Alternative Names: Beta secretase inhibitor - Eli Lilly; LY-2886721; β secretase inhibitor - Eli Lilly

Latest Information Update: 07 Oct 2013

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 18 Sep 2013 Discontinued - Phase-I for Alzheimer's disease (in volunteers) in USA (PO)
  • 18 Sep 2013 Discontinued - Phase-I/II for Alzheimer's disease in USA, Italy, the Netherlands, Spain and Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top